drugset / Trial / NCT06734130
Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective single center phase IIa open label nonrandomized study, which aims to test the hypothesis that the duration of castration sensitive phase of stage IV prostate cancer can be prolonged with adaptive androgen deprivation therapy (ADT) and Docetaxel.
Timeline
- Start
- 2025-01-10
- Primary completion
- 2029-01
- Completion
- 2029-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | 75 mg/m2 | Intravenous |
| Background | Apalutamide | Small molecule | — | — |
| Background | Darolutamide | Other / unclassified | — | — |
| Background | Degarelix | Other / unclassified | — | — |
| Background | Enzalutamide | Other / unclassified | — | — |
| Background | Leuprolide | Other / unclassified | — | — |
| Background | Relugolix | Small molecule | — | — |
| Background | Triptorelin | Other / unclassified | — | — |